KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV Stock Report

Market Cap: US$446.2m

KalVista Pharmaceuticals Management

Management criteria checks 1/4

KalVista Pharmaceuticals' CEO is Ben Palleiko, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $6.77M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth $2.48M. The average tenure of the management team and the board of directors is 1.5 years and 3.3 years respectively.

Key information

Ben Palleiko

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage8.6%
CEO tenureless than a year
CEO ownership0.6%
Management average tenure1.5yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025

Dec 18

KalVista: Upcoming PDUFA, But Not Without Risks

Nov 25

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceticals GAAP EPS of -$0.94

Sep 08

KalVista reaches five-month high as rival tumbles on hereditary angioedema

Aug 22

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Jul 07

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02
Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24
We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

CEO Compensation Analysis

How has Ben Palleiko's remuneration changed compared to KalVista Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-US$156m

Jul 31 2024n/an/a

-US$142m

Apr 30 2024US$7mUS$580k

-US$127m

Jan 31 2024n/an/a

-US$108m

Oct 31 2023n/an/a

-US$101m

Jul 31 2023n/an/a

-US$95m

Apr 30 2023US$2mUS$515k

-US$93m

Jan 31 2023n/an/a

-US$91m

Oct 31 2022n/an/a

-US$92m

Jul 31 2022n/an/a

-US$89m

Apr 30 2022US$3mUS$490k

-US$82m

Jan 31 2022n/an/a

-US$73m

Oct 31 2021n/an/a

-US$61m

Jul 31 2021n/an/a

-US$52m

Apr 30 2021US$1mUS$435k

-US$46m

Jan 31 2021n/an/a

-US$38m

Oct 31 2020n/an/a

-US$37m

Jul 31 2020n/an/a

-US$33m

Apr 30 2020US$1mUS$435k

-US$29m

Jan 31 2020n/an/a

-US$31m

Oct 31 2019n/an/a

-US$26m

Jul 31 2019n/an/a

-US$23m

Apr 30 2019US$2mUS$366k

-US$21m

Jan 31 2019n/an/a

-US$13m

Oct 31 2018n/an/a

-US$14m

Jul 31 2018n/an/a

-US$16m

Apr 30 2018US$821kUS$340k

-US$16m

Compensation vs Market: Ben's total compensation ($USD6.77M) is above average for companies of similar size in the US market ($USD2.23M).

Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.

CEO

Ben Palleiko (58 yo)

less than a year

Tenure

US$6,772,197

Compensation

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.56%
$ 2.5m
Christopher Yea
Chief Development Officer9.2yrsUS$1.37m0.18%
$ 823.0k
Paul Audhya
Chief Medical Officer3.7yrsUS$1.83m0.20%
$ 876.0k
Brian Piekos
Chief Financial Officerless than a yearno datano data
Jeb Ledell
Chief Operating Officerless than a yearno datano data
Ryan Baker
Head of Investor Relationsno datano datano data
Brian Krex
General Counselno datano datano data
Jarrod Aldom
Vice President of Corporate Communicationsno datano datano data
Rachel Morten
Senior Vice President of Regulatory Affairs & QAno datano datano data
Michael Smith
Senior Vice President of Development5.7yrsno datano data
Nicole Sweeny
Chief Commercial Officer1.5yrsno datano data
Stephen Donnelly
Director of Finance and Company Secretaryno datano datano data

1.5yrs

Average Tenure

51yo

Average Age

Experienced Management: KALV's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.56%
$ 2.5m
Edward Unkart
Independent Director10.1yrsUS$136.60k0%
$ 0
Brian J. Pereira
Independent Chairman5.9yrsUS$161.60k0%
$ 0
Laurence Reid
Directorless than a yearno datano data
Nancy Stuart
Independent Director3.8yrsUS$136.60k0%
$ 0
William Fairey
Independent Directorless than a yearUS$143.78kno data
Tomas Kiselak
Board Observer9.5yrsno datano data
Patrick Treanor
Independent Director2.7yrsUS$124.10k0%
$ 0

3.3yrs

Average Tenure

60yo

Average Age

Experienced Board: KALV's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 05:46
End of Day Share Price 2025/01/06 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KalVista Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
null nullBTIG
Charles DuncanCantor Fitzgerald & Co.